eXCELL Biotherapeutics Inc. announces the company has been awarded with Small and Medium Enterprise Administration, Ministry of Economic Affairs SBIR (The Small Business Innovation Research) grant for the proposal “Novel Xenogeneic Cell-Based Cancer Immunotherapy Products – CMC (Chemistry, Manufacturing and Controls Chemical Manufacturing Control) Pilot Study創新異種異體細胞癌症免疫治療產品–CMC (Chemistry, Manufacturing And Controls化學製造管制)先期研究計畫”.
Feb. 2, 2023– eXCELL Biotherapeutics Inc., a biopharmaceutical company advancing xenogeneic cellular therapeutics to address unmet medical needs in oncology and infectious diseases, today announced that the company has been awarded with Small and Medium Enterprise Administration, Ministry of Economic Affairs SBIR (The Small Business Innovation Research) grant.
[icon name=”paper-plane” prefix=”fas”]
The proposed project is based on the novel xenogeneic cell immunotherapy platform developed by eXCELL. The xenogeneic cell product candidates against cancer will be manufactured experimentally for producing clinical-grade cells to be tested for their therapeutic effects and safety profiles in preclinical studies to further demonstrate the utility of therapeutic xenogeneic cells.